Loading clinical trials...
Loading clinical trials...
Valeur Pronostique Dans Une Population d'Amylose Cardiaque Des paramètres échocardiographiques basée Sur Une Approche d'Apprentissage Automatique
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hôpitaux Universitaires Henri Mondor
Créteil, France
CHRU de Nancy
Nancy, France
CHU de Rennes Hôpital Pontchaillou
Rennes, France
CHU de Toulouse
Toulouse, France
Start Date
September 29, 2023
Primary Completion Date
March 31, 2024
Completion Date
March 31, 2024
Last Updated
March 28, 2024
1,000
ESTIMATED participants
Lead Sponsor
Pr. Nicolas GIRERD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions